Amgen (AMGN) Construction in Progress (2009 - 2022)
Amgen (AMGN) posted quarterly Construction in Progress of $1.2 billion for Q4 2022, up 22.9% year-over-year from $987.0 million in Q4 2021, and up 22.9% quarter-over-quarter from $987.0 million in Q4 2021.
Amgen (AMGN) Construction in Progress (2009 - 2022) Analysis & Trends
Amgen's Construction in Progress history runs 14 years deep, the most recent figure standing at $1.2 billion for Q4 2022.
- In Q4 2022, Construction in Progress rose 22.9% year-over-year to $1.2 billion; the TTM figure through Dec 2022 stood at $1.2 billion (up 22.9% YoY), while the FY2022 annual figure was $1.2 billion, up 22.9% from the prior year.
- Construction in Progress for Q4 2022 stood at $1.2 billion, up from $987.0 million in the prior quarter.
- The five-year high for Construction in Progress was $1.2 billion in Q4 2022, with the low at $907.0 million in Q4 2019.
- The 5-year median for Construction in Progress is $953.0 million (2018), against an average of $995.0 million.
- The sharpest annual moves came in 2019 and 2022: Construction in Progress retreated 4.83% in 2019, then increased 22.9% in 2022.
- Amgen's Construction in Progress stood at $953.0 million in 2018, then decreased by 4.83% to $907.0 million in 2019, then gained by 0.88% to $915.0 million in 2020, then grew by 7.87% to $987.0 million in 2021, then climbed by 22.9% to $1.2 billion in 2022.
- Business Quant data shows AMGN's Construction in Progress at $1.2 billion in Q4 2022, $987.0 million in Q4 2021, and $915.0 million in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 654.21 Bn | 633.45 Bn | 17.26 Bn | - |
| 2 | AbbVie | 468.90 Bn | 462.33 Bn | 12.70 Bn | - |
| 3 | Merck | 378.18 Bn | 371.04 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 302.34 Bn | 294.65 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.60 Bn | 252.70 Bn | 12.86 Bn | - |
| 6 | Amgen | 236.39 Bn | 222.40 Bn | 7.24 Bn | - |
| 7 | Gilead Sciences | 182.58 Bn | 179.41 Bn | 6.22 Bn | - |
| 8 | Pfizer | 161.17 Bn | 149.47 Bn | 10.94 Bn | - |
| 9 | Gsk | 105.37 Bn | 101.20 Bn | 8.24 Bn | - |
| 10 | Sanofi | 54.98 Bn | 47.60 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 1.21 Bn |
| Dec 31, 2021 | 987.00 Mn |
| Dec 31, 2020 | 915.00 Mn |
| Dec 31, 2019 | 907.00 Mn |
| Dec 31, 2018 | 953.00 Mn |
| Dec 31, 2017 | 834.00 Mn |
| Dec 31, 2016 | 745.00 Mn |
| Dec 31, 2015 | 746.00 Mn |
| Dec 31, 2014 | 1.18 Bn |
| Dec 31, 2013 | 1.12 Bn |
| Dec 31, 2012 | 1.07 Bn |
| Dec 31, 2011 | 744.00 Mn |
| Dec 31, 2010 | 631.00 Mn |
| Dec 31, 2009 | 910.00 Mn |